| Document |
Document Title |
|
JP2008533088A |
New N-hydroxyamides of n-alkyl carboxylic acids omega substituted with suitable tricyclic systems characterised by a central 7-membered ring, having activity as inhibitors of histone deacetylase (HDAC).
|
|
JP2008531690A |
Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals i...
|
|
JP2008530129A |
The invention features charge-modified antidepressants and compounds conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage. The invention provides a method for treating a patient having an inflam...
|
|
JP2008517993A |
The present invention relates to new compounds represented by Formula I: wherein M represents a macrolide subunit of the substructure VIII: L represents the chain of the substructure IX or XIII: -X 1 -(CH...
|
|
JP2008515850A |
Enantiopure heterocyclic compound Enantiopure heterocyclic compound of formula (I) in which J is chosen from C, N, O and S; Z is H or a group for protecting the amino functional group, R3 denotes H or an organic residue, m is 0, 1 or 2 a...
|
|
JP4081167B2 |
Guanidine and cycloguanidine derivatives of formula A-B-D-E-F-G (I) and their salts are new. A = R<2>R<3>N-C(=NR<2>)NR<2>Z- or a group of formula (a) or (b); Z = C(Q) or S(O)n; Q = O or S; n = 1 or 2; R = 5-10 membered mono- or polycycli...
|
|
JP2008509999A |
The present invention is directed to novel benzoxazepine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and diseases mediated by an estrogen receptor.
|
|
JP2008509982A |
A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.
|
|
JP4071000B2 |
This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: wherein X, Y, and Z are O, S or NR5, and the other substituents are as defined in the specification; an...
|
|
JP2008509074A |
The present invention provides a novel drug which is useful as a preventive and/or therapeutic agent for various diseases involved in elevation of CRP level, in particular, inflammatory disease and cancer comprising a compound having inh...
|
|
JP4065573B2 |
Cyclic products are prepared by selective olefin metathesis of bifunctional or polyfunctional substrates in the presence of one or several homogeneous or heterogeneous metathesis catalysts in a reaction medium. The invention is character...
|
|
JP4043363B2 |
The present invention relates to alanine 2,6-dialkoxyphenyl ester derivatives having the general formula I The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of these alanine 2,6-dialkox...
|
|
JP2008501629A |
The present invention provides an industrial production method with a short process having a high yield of an aliphatic cyclic carboxamide having carboxyl group, which comprises reacting functional group-selectively using an inexpensive ...
|
|
JP4033886B2 |
A compound of formula (I), or a pharmaceutically acceptable derivative thereof, wherein V represents -(CH)(O)-, -CO-, or -CH(Calkyl)-; W is -0-, -S(O), or -N(R)-Rrepresents H, Calkyl, (CH)COR, CO(CH)NRR, SOR, (CH)OR, (CH),NRR, or (CH)het...
|
|
JP2007332154A |
To provide a compound more useful for a medicine, useful for prevention and medication of hyperlipidemia through activities of lowering cholesterol-level and lowering triglyceride-level by inhibitory activities to enzymes for synthesizin...
|
|
JP4024149B2 |
The present invention relates to the compounds of formula (I): in which A is a group of formula (a) or (b) in which R represents a hydrogen or halogen atom, an —S(O)z(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —SO2NH(C1-C4)...
|
|
JP4021612B2 |
|
|
JP4021959B2 |
Compounds, useful as plant fungicides, having the formula (I): or a stereoisomer thereof, wherein A is CH or N, B is OCH3 or NHCH3, X is CH2, CH2O, O or S, Y is R<1>-C=C-R<2> or R<1>-CH-CH-R<2> wherein R<1> and R<2> are independently H, ...
|
|
JP2007534656A |
Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some ...
|
|
JP2007533718A |
Compounds having therapeutic utility are of general formula (1) wherein R, is H, C 1-C6 alkyl optionally substituted with F or C3-C6 cycloalkyl or C2-C4 alkenyl; A is O, CH2 or S(O)n where n is 0-2; one of W, X, Y and Z is N, CH or CR3 a...
|
|
JP3995404B2 |
A benzoxazepine derivative having the general formula (I) and its salts and medicaments containing the same as effective ingredients: wherein, n is an integer of 2 to 5, R<1> indicates a hydrogen atom, halogen atom, C1 to C4 lower alkyl ...
|
|
JP3988832B2 |
To provide an excellent URAT1 (urate transporter 1) activity inhibitor effective in treatment, etc., of pathological conditions in which uric acid is associated such as hyperuricemia, gouty node, acute gouty arthritis, chronic gouty arth...
|
|
JP3955211B2 |
This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I:wherein X, Y, and Z are O, S, or NR<4>, and the other substituents are as defined in the specification; ...
|
|
JP3942670B2 |
To obtain a new compound reducing a high cardiac filling pressure occurring in heart failure to thereby lessen a burden to heart because of a neutral endopeptidase inhibitory activity, enhancing a uretic function and useful for the heart...
|
|
JP3935071B2 |
Compounds according to general formulae (1 and 2), wherein G1 is an azepine derivative and G2 is a group according to general formulae (9-11) are new. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceuti...
|
|
JP2007513936A |
A process for increasing the optical purity of a mixture of enantiomers of nefopam uses a substantially single enantiomer of a O,O-diaroyltartaric acid as a resolving agent, via a bisnefopam salt of the acid. This salt is new.
|
|
JP2007512319A |
The present invention is directed to the use of S-(-)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for prevention and/or treatment of a cardiovascular disease ...
|
|
JP3900746B2 |
To obtain a photographic processing agent composition giving a stable processing solution free from precipitation and the occurrence of sludge due to the presence of metal ions by incorporating a specified compound. The processing agent ...
|
|
JP3887785B2 |
PCT No. PCT/EP95/04197 Sec. 371 Date Apr. 25, 1997 Sec. 102(e) Date Apr. 25, 1997 PCT Filed Oct. 25, 1995 PCT Pub. No. WO96/14321 PCT Pub. Date May 17, 1996This invention concerns the compounds of formula (I), the pharmaceutically accept...
|
|
JP2007045838A |
To provide a compound that shows vasopressin antagonizing activity and can be used for treating dysmenorrhea (primary and secondary).A compound represented by formula (I) or its pharmaceutically acceptable derivative is used as a medicine.
|
|
JP2007039466A |
To provide an excellent URAT1 (urate transporter 1) activity inhibitor effective in treatment, etc., of pathological conditions in which uric acid is associated such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty ar...
|
|
JP2007502857A |
The present disclosure relates to new 11-O-alkyl macrolides and azalides and pharmaceutically acceptable salts and solvates thereof, and to pharmaceutical compositions thereof. The disclosure also relates to a process for the preparation...
|
|
JP2007502278A |
The present invention is directed to compounds of formula I which are inhibitors of the beta-secretase enzyme and that are useful in the treatment or prevention of diseases in which the beta-secretase enzyme is involved, such as Alzheime...
|
|
JP3865829B2 |
To obtain a new compound having action enhancing action of a retinoid such as retinoic acid and useful for a medicinal composition. This retinoid action enhancing compound is represented by formula I (R1 is H or 1-6C alkyl; R2 and R3 are...
|
|
JP2006522012A |
A compound of the general formula (1): wherein one of W, X, Y and Z is N or CR 4 and the others are each CH; and R 4 is a specified substituent. These compounds inhibit monoamine reuptake, and are useful in the treatment of pain, emesis ...
|
|
JP3819759B2 |
To provide a compound having excellent choline esterase inhibitory activity and monoamine intake inhibitory activity, thus useful as a prophylactic/ therapeutic agent for senile dementia. This compound (a salt thereof) is shown by the fo...
|
|
JP3813152B2 |
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds...
|
|
JP3812952B2 |
Disclosed are compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits...
|
|
JP3810450B2 |
PURPOSE: To obtain a new condensed ring compound which is useful in the prophylaxis and therapy for hypercholesterolemia and coronary ayteriosclerosis because it has excellent inhibitory action against squalene synthase. CONSTITUTION: A ...
|
|
JP3789468B2 |
A benzazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPIIbIIIa receptor and is provided in therapeutic compositions for the treatment o...
|
|
JP2006514934A |
Loxapine, amoxapine, or salts or prodrugs of either, is effective in alleviating pain, particularly headache pain such as migraine, cluster headaches and tension headaches. Preferably the loxapine or amoxapine is administered systemicall...
|
|
JP2006514633A |
Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.
|
|
JP2006513162A |
Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparati...
|
|
JP2006511502A |
The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacologi...
|
|
JP3764180B2 |
PURPOSE: To obtain a new compound having inhibiting actions on the synthesis of squalene and antifungal actions and effectively usable as a therapeutic agent for hypercholesterolemia, etc. CONSTITUTION: This compound (salt) is expressed ...
|
|
JP2006510697A |
Use of compounds of formula (I):
|
|
JP2006503869A |
10-Alkyl-11-oxo-10,11-dihydro-dibenz-(b,f)(1,4)-azepine derivatives (I) are new. Dibenzoxazepinones of formula (I) and their salts, solvates and solvated salts are new. Y = 1-6C alkylidene, optionally (i) containing one or more double or...
|
|
JPWO2004026292A1 |
Equation (I)(A indicates an alkoxycarbonylalkyl group, etc., R indicates a hydroxyl group which may be protected, or A and R together form a 6- or 7-membered ring containing an oxygen atom, and B indicates a carbonyl. Indicates a group o...
|
|
JP2005350482A |
To provide a method for treating a female suffering from female sexual dysfunction (FSD), in particular female sexual arousal dysfunction (FSAD).The method comprises delivering to the female with FSD, especially FSAD an agent that is cap...
|
|
JP2005343790A |
To obtain an excellent medicinal composition for treating Alzheimer's disease, mental illness, adolescent insanity, manic depression, migraine, lactation disorder, dementia, autism, hypertension, glaucoma, pain, thromboembolism, arrhythm...
|
